We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+43.82%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.32B
AUM Growth
+$367M
Cap. Flow
+$106M
Cap. Flow %
8.07%
Top 10 Hldgs %
60.28%
Holding
65
New
6
Increased
15
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$74.1M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$64.1M
3
CYTK icon
Cytokinetics
CYTK
+$31.2M
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$19.8M
5
XOMA
Xoma
XOMA
+$18.9M

Top Sells

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$46.6M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$24.1M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$24.1M
4
MRUS
Merus
MRUS
+$23.6M
5
BPMC
Blueprint Medicines
BPMC
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 95.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SURF
51
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.04M 0.15%
1,086,251
– –
RGLS
52
DELISTED
Regulus Therapeutics
RGLS
$1.81M 0.14%
203,570
– –
FSTX
53
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.5M 0.11%
237,925
-106,785
-31% -$1.36M
CFRX
54
DELISTED
ContraFect Corporation
CFRX
$1.18M 0.09%
2,374
– –
FRTX
55
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$664K 0.05%
9,840
+4,771
+94% +$552K
ELDN icon
56
Eledon Pharmaceuticals
ELDN
$259M
$481K 0.04%
46,049
– –
KZR
57
DELISTED
Kezar Life Sciences
KZR
$468K 0.04%
+11,671
New +$359K
LKFT
58
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.79B
– –
-305,076
Closed -$46.6M
MREO
59
Mereo BioPharma
MREO
$52.4M
– –
-523,382
Closed -$1.52M
DCPH
60
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-710,697
Closed -$24.1M
MRTX
61
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-308,984
Closed -$24.1M
KDNY
62
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-202,000
Closed -$1.07M
ALBO
63
DELISTED
Albireo Pharma Inc
ALBO
– –
-29,000
Closed -$580K
CCXI
64
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-1,414,515
Closed -$9.59M
DRNA
65
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-1,223,925
Closed -$17.6M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2019 Portfolio in Review

As of Q4 2019, BVF Inc held 65 positions worth $1.32B, up 39% from $952M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

BVF Inc deployed $106M of net new capital in Q4 2019, opening 6 new positions and adding to 15 existing holdings. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,716,734 shares worth $94M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $23.6M trimmed.

  • BVF Inc's largest Q4 2019 buy was Principia Biopharma Inc. Common Stock: 1,716,734 shares worth $94M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q4 2019, an estimated $74.1M increase.
  • BVF Inc's biggest Q4 2019 reduction was Merus, cutting an estimated $23.6M.
  • BVF Inc fully exited Lakefront Biotherapeutics American Depositary Shares in Q4 2019, selling an estimated $46.6M.
  • BVF Inc's ten largest holdings make up 60% of its $1.32B portfolio in Q4 2019.
  • BVF Inc opened 6 new positions and closed 8 in Q4 2019.
  • BVF Inc's portfolio value rose 39% quarter-over-quarter to $1.32B.

Based on BVF Inc's 13F filing for Q4 2019, filed 14 Feb 2020.